{"id":49200,"date":"2022-10-05T17:01:47","date_gmt":"2022-10-05T15:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/"},"modified":"2022-10-05T17:01:47","modified_gmt":"2022-10-05T15:01:47","slug":"medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/","title":{"rendered":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022)"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Company to present <\/i><i>Phase 1 data <\/i><i>from its lead program, MDK-703, an Interleukin-7 (IL-7) mimetic with an extended half-life<\/i>\n<\/li>\n<li>\n<i>Additional poster showcases preclinical proof-of-concept data characterizing MDK-1654, a differentiated synthetic peptide that is both an IL-7 receptor and non-alpha IL-2\/15 receptor agonist<\/i>\n<\/li>\n<\/ul>\n<p>MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE\u2122 technology, announced today that it will deliver two poster presentations at the upcoming Society for Immunotherapy of Cancer\u2019s 37<sup>th<\/sup> Annual Meeting (SITC 2022), taking place virtually and in Boston on November 8-12.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/5\/MedikineLogo_03-02-2022_%401000px.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg\"><\/a><\/p>\n<p>\nThe first poster presentation will highlight preliminary Phase 1 safety, tolerability, and pharmacokinetic\/pharmacodynamic data on Medikine\u2019s lead program, MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikine\u2019s innovative platform technology. A second poster will detail preclinical data on MDK-1654, Medikine\u2019s dual-acting agonist that incorporates both IL-7 and non-alpha IL-2\/15 PEPTIKINEs.\n<\/p>\n<p>\nDetails on the poster presentations are as follows:\n<\/p>\n<p>\n<b>Title<\/b>: A Phase 1 Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of MDK-703, an IL-7 Mimetic With Extended Half-life\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Abstract #<\/b>: 625\n<\/li>\n<li>\n<b>Presenter<\/b>: Ron Barrett, PhD, Medikine\n<\/li>\n<li>\n<b>Date\/Time<\/b>: Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST\n<\/li>\n<\/ul>\n<p>\n<b>Title<\/b>: MDK1654: A Branched Synthetic Peptide that Activates Both the IL-7 Receptor and the \u03b2\u03b3c Form of the IL-2\/15 Receptor\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Abstract #<\/b>: 1097\n<\/li>\n<li>\n<b>Presenter<\/b>: Angie Park, PhD, Medikine\n<\/li>\n<li>\n<b>Date\/Time<\/b>: Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST\n<\/li>\n<\/ul>\n<p>\nFull abstracts will be made available online and will be included in the <i>Journal for ImmunoTherapy of Cancer (JITC) <\/i>supplement on November 7. Posters will also be available on the Medikine website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.medikine.com&amp;esheet=52937704&amp;newsitemid=20221005005563&amp;lan=en-US&amp;anchor=www.Medikine.com&amp;index=1&amp;md5=534dc9efed58416103f647e529121668\" rel=\"nofollow noopener\" shape=\"rect\">www.Medikine.com<\/a> following the poster presentations.\n<\/p>\n<p>\n<b>ABOUT MEDIKINE<\/b>\n<\/p>\n<p>\nMedikine is a biopharmaceutical company with a mission to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular \u201cPEPTIKINES\u201d- peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. These PEPTIKINES are engineered for low immunogenicity and are readily amenable to the incorporation of targeting and other pharmacological features.\n<\/p>\n<p>\nMedikine\u2019s lead candidate, MDK-703, currently in a Phase 1 clinical trial in healthy volunteers, is an IL-7 PEPTIKINE fused to an immunoglobulin Fc-domain. MDK-703 emulates the beneficial properties of IL-7, a cytokine critical for maintenance of T cell responses.\n<\/p>\n<p>\nFor more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.medikine.com&amp;esheet=52937704&amp;newsitemid=20221005005563&amp;lan=en-US&amp;anchor=www.medikine.com&amp;index=2&amp;md5=c8af8c8e8826dc484ce3858b15f3f556\" rel=\"nofollow noopener\" shape=\"rect\">www.medikine.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>MEDIA CONTACT:<\/b><br \/>Dan Boyle<br \/>\n<br \/>The Grace Communication Group<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;&#111;:d&#x61;&#x6e;&#x40;&#x67;&#114;&#97;ce&#x67;&#x72;&#x6f;&#x75;&#112;&#46;us\" rel=\"nofollow noopener\" shape=\"rect\">&#x64;&#x61;&#x6e;&#x40;&#x67;&#x72;&#x61;&#x63;&#x65;&#x67;&#x72;&#x6f;&#x75;&#x70;&#x2e;&#x75;&#x73;<\/a><br \/>(818) 209-1692\n<\/p>\n<p>\n<b>INVESTOR CONTACT:<\/b><br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#105;&#x6e;&#x76;e&#115;&#x74;o&#114;&#x73;&#x40;m&#101;&#x64;i&#107;&#x69;&#x6e;&#101;&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#110;&#118;&#x65;&#x73;&#116;&#111;&#x72;&#x73;&#64;&#109;&#x65;&#x64;&#105;&#107;&#x69;&#x6e;&#101;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to present Phase 1 data from its lead program, MDK-703, an Interleukin-7 (IL-7) mimetic with an extended half-life Additional poster showcases preclinical proof-of-concept data characterizing MDK-1654, a differentiated synthetic peptide that is both an IL-7 receptor and non-alpha IL-2\/15 receptor agonist MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49200","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company to present Phase 1 data from its lead program, MDK-703, an Interleukin-7 (IL-7) mimetic with an extended half-life Additional poster showcases preclinical proof-of-concept data characterizing MDK-1654, a differentiated synthetic peptide that is both an IL-7 receptor and non-alpha IL-2\/15 receptor agonist MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T15:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022)\",\"datePublished\":\"2022-10-05T15:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/\"},\"wordCount\":438,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005563\\\/en\\\/1516867\\\/21\\\/MedikineLogo_03-02-2022_%401000px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/\",\"name\":\"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005563\\\/en\\\/1516867\\\/21\\\/MedikineLogo_03-02-2022_%401000px.jpg\",\"datePublished\":\"2022-10-05T15:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005563\\\/en\\\/1516867\\\/21\\\/MedikineLogo_03-02-2022_%401000px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005563\\\/en\\\/1516867\\\/21\\\/MedikineLogo_03-02-2022_%401000px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/","og_locale":"en_US","og_type":"article","og_title":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022) - Pharma Trend","og_description":"Company to present Phase 1 data from its lead program, MDK-703, an Interleukin-7 (IL-7) mimetic with an extended half-life Additional poster showcases preclinical proof-of-concept data characterizing MDK-1654, a differentiated synthetic peptide that is both an IL-7 receptor and non-alpha IL-2\/15 receptor agonist MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-05T15:01:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022)","datePublished":"2022-10-05T15:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/"},"wordCount":438,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/","url":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/","name":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg","datePublished":"2022-10-05T15:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221005005563\/en\/1516867\/21\/MedikineLogo_03-02-2022_%401000px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medikine-to-present-preliminary-phase-1-clinical-trial-results-for-mdk-703-at-the-society-for-immunotherapy-of-cancers-37th-annual-meeting-sitc-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49200"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49200\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}